z-logo
open-access-imgOpen Access
Matriptase drives early-onset intestinal failure in a mouse model of congenital tufting enteropathy
Author(s) -
Roman Szabo,
LuLu K. Callies,
Thomas H. Bugge
Publication year - 2019
Publication title -
development
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.754
H-Index - 325
eISSN - 1477-9129
pISSN - 0950-1991
DOI - 10.1242/dev.183392
Subject(s) - biology , enteropathy , mutation , cancer research , atrophy , microbiology and biotechnology , gene , disease , medicine , genetics
Syndromic congenital tufting enteropathy (CTE) is a life-threatening recessive human genetic disorder, which is caused by mutations in SPINT2, encoding the protease inhibitor, HAI-2, and is characterized by severe intestinal dysfunction. We recently reported the generation of a Spint2-deficient mouse model of CTE. Here, we show that the CTE-associated early-onset intestinal failure and lethality of Spint2-deficient mice is caused by unchecked activity of the serine protease, matriptase. Macroscopic and histological defects observed in the absence of HAI-2, including villous atrophy, luminal bleeding, loss of mucin-producing goblet cells, loss of defined crypt architecture and the resulting acute inflammatory response in the large intestine, were all prevented by intestinal-specific inactivation of the St14 gene encoding matriptase. The CTE-associated loss of the cell junctional proteins EpCAM and claudin-7 was also prevented. As a result, inactivation of intestinal matriptase allowed Spint2-deficient mice to gain weight after birth and dramatically increased their life span. These data implicate matriptase as a causative agent in development of CTE and may provide a new target for the treatment of CTE in patients carrying SPINT2 mutations.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here